Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis International (Details)

v3.21.2
Licensing and Other Arrangements - Novartis International (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 21, 2020
USD ($)
Sep. 30, 2015
item
Jun. 30, 2021
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2020
USD ($)
Licensing and other arrangements                      
Revenue from contracts with customers         $ 525 $ 53 $ 544 $ 553      
Novartis Note                      
Licensing and other arrangements                      
Reduction in debt obligation $ 7,300   $ 9,100                
Novartis International | License Agreement                      
Licensing and other arrangements                      
Agreement termination prior written notice period   180 days                  
Number of performance obligations | item   1                  
Cash payment received 17,700                 $ 37,000  
Revenue from contracts with customers 25,000       0 $ 0 0 $ 0 $ 10,000 $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 445,000     $ 480,000              
Royalty payment period   10 years                  
Contract assets     0   0   0       $ 0
Contract liabilities     0   0   0       0
Capitalized contract costs     $ 0   $ 0   $ 0       $ 0